CGM for All: Key Takeaways for Patients, Providers, and Payers

In the final episode, 'CGM for All: Key Takeaways for Patients, Providers, and Payers,' the panelists explored the following critical questions:

1. For patients on non-insulin therapies, does this study shift your threshold for recommending CGM, and how do you navigate the insurance coverage challenges that may accompany that conversation?
2. In light of the ADA's recommendation on initial and ongoing education to utilize CGMs, how can providers best deliver that education?
3. What are the main takeaways from the 2026 ADA guideline CGM updates for a. patients, b. providers, and c. payers?

Led by the moderator, Estay Greene and Victoria Bouhairie examined the growing evidence supporting CGM use across both insulin and non-insulin-dependent patients, reinforcing that the 2026 ADA guideline expansions reflect real-world clinical benefit for a broad spectrum of individuals with diabetes. The discussion highlighted the importance of a multidisciplinary approach to CGM education, leveraging trained staff, diabetes education specialists, and telehealth follow-up to ensure patients are equipped to use their devices effectively. The experts closed with a compelling stakeholder-specific summary of key takeaways: for patients, CGM provides actionable real-time insights: for providers, it enables more personalized, data-driven therapeutic decisions; and for payers, the evidence supports expanding access beyond A1C thresholds, as broader CGM use drives reductions in glucose variability, acute complications, and the long-term total cost of diabetes care.
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
Thank you for watching this Between The Lines series on diabetes. Please subscribe to our newsletter for information on upcoming video series.